Corticosteroid treatment modulates immune cell populations in the glioblastoma microenvironment

Clicks: 7
ID: 331606
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #138 of 144 articles by views in Neuro-Oncology Advances

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 144 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Corticosteroids play a crucial role in alleviating tumor-associated edema in patients with brain tumors. However, their impact on the tumor microenvironment within glioblastoma remains largely unexplored. In the context of increasing interest in immunotherapy and limited clinical progress for glioblastoma patients, it is important to understand how corticosteroid therapy influences the immune microenvironment. Methods This study involved 80 glioblastoma patients, 41 of whom received corticosteroids preoperatively and 39 who did not. The groups were balanced for key clinical prognostic parameters. Through immunohistochemical staining and image analysis-based software classifiers, we quantitatively assessed a broad marker panel covering immune, myeloid, hypoxia-related, and tumor-associated features of the glioblastoma microenvironment. Results Our analysis revealed a more than two-fold decrease in FOXP3+ regulatory T cells in glioblastoma tissue samples from patients who received corticosteroids. In dose-subgroup analyses, high-dose corticosteroid exposure was associated with increased CD68+ and CD204+ myeloid/macrophage-marker abundance. CD8 and CD4 T cell counts, as well as CD86, TMEM119, HIF-1α, PD-L1, and SOX2, remained similar across all groups. Conclusions Our findings suggest that corticosteroid treatment is associated with selective changes in T cell and myeloid/macrophage-marker abundance within the tumor microenvironment. These findings highlight corticosteroid exposure as an important factor to consider when interpreting immune profiles and developing immune-based therapies in glioblastoma.
Reference Key
openalex_W7220843696 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Rune Just Clausen, Sofie Sorgenfri Hjerrild Nielsen, Julie Jacobsen, Line Viftrup Buchwald, Vilde Pedersen, Nadine Margaretha Hammouda, Nicolai Schou Bager, Kirsten Grunnet, Hans Skovgaard Poulsen, Simone Maarup, Benedikte Hasselbalch, Thomas Urup, Signe Regner Michaelsen, Sara Blaabjerg Artzi, Bjarne Winther Kristensen
Are you one of these authors? Claim your profile
Journal Neuro-Oncology Advances
Year 2026
DOI
10.1093/noajnl/vdag258
URL
https://doi.org/10.1093/noajnl/vdag258
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.